

## **Determinants of antibody responses to two doses of ChAdOx1 nCoV-19 or BNT162b2 and a subsequent booster dose of BNT162b2 or mRNA-1273: population-based cohort study (COVIDENCE UK)**

David A Jolliffe<sup>1,2†</sup>

Sian E Faustini<sup>3</sup>

Hayley Holt<sup>1,2,4\*</sup>

Natalia Perdek<sup>1</sup>

Sheena Maltby<sup>1</sup>

Mohammad Talaei<sup>2</sup>

Matthew Greenig<sup>1</sup>

Giulia Vivaldi<sup>1,2</sup>

Florence Tydeman<sup>1,2</sup>

Jane Symons<sup>5</sup>

Gwyneth A Davies<sup>6</sup>

Ronan A Lyons<sup>6</sup>

Christopher J Griffiths<sup>2,4</sup>

Frank Kee<sup>7</sup>

Aziz Sheikh<sup>8</sup>

Seif O Shaheen<sup>2</sup>

Alex G Richter<sup>3</sup>

Adrian R Martineau<sup>1,2,4†</sup>

<sup>1</sup>Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK

<sup>2</sup>Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK

<sup>3</sup>Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

<sup>4</sup>Asthma UK Centre for Applied Research, Queen Mary University of London, London, UK

<sup>5</sup>Jane Symons Media, London, UK

<sup>6</sup>Population Data Science, Swansea University Medical School, Singleton Park, Swansea, UK

<sup>7</sup>NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.  
<sup>7</sup>Centre for Public Health Research (NI), Queen's University Belfast, Belfast, UK

<sup>8</sup>Usher Institute, University of Edinburgh, Edinburgh, UK

<sup>†</sup>Corresponding authors: Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark St, London E1 2AT, UK

Email: [d.a.jolliffe@qmul.ac.uk](mailto:d.a.jolliffe@qmul.ac.uk) or [a.martineau@qmul.ac.uk](mailto:a.martineau@qmul.ac.uk)

Word count: 3,877

## Summary

**Background:** Antibody responses to SARS-CoV-2 vaccination vary for reasons that remain poorly understood.

**Methods:** We tested for presence of combined IgG, IgA and IgM (IgGAM) anti-spike antibodies before and after administration of two doses of ChAdOx1 nCoV-19 (ChAdOx1, Oxford-AstraZeneca) or BNT162b2 (Pfizer-BioNTech) in UK adults participating in a population-based longitudinal study who received their first dose of vaccine from December 15, 2020 to July 10, 2021. Information on sixty-six potential sociodemographic, behavioural, clinical, pharmacological and nutritional determinants of serological response to vaccination was captured using serial online questionnaires. We used logistic regression to estimate multivariable-adjusted odds ratios (aORs) for associations between independent variables and risk of seronegativity following two vaccine doses. Participants who were seronegative after receiving two vaccine doses were offered an additional antibody test following subsequent administration of a 'booster' dose of BNT162b2 or mRNA-1273 (Moderna) from September 23 to December 12, 2021.

**Findings:** Serology results following two vaccine doses were available for 9,101 participants, of whom 5,770 (63.4%) received ChAdOx1 and 3,331 (36.6%) received BNT162b2. Anti-spike IgGAM was undetectable in 378 (4.2%) participants at a median of 8.6 weeks (IQR 6.4-10.7 weeks) after their second dose of vaccine. Seronegativity following two doses of SARS-CoV-2 vaccination was associated with administration of ChAdOx1 vs BNT162b2 (aOR 7.03, 95% CI 4.39-11.24), shorter interval between first and second vaccine doses (aOR 2.37, 1.06-5.26, for <6 weeks vs >10 weeks; aOR 1.59, 1.18-2.13, for 6-10 weeks vs >10 weeks), poorer self-assessed general health (aOR 3.33, 1.49-7.46, for poor vs excellent), immunodeficiencies (aOR 6.75, 2.63-17.35) and prescription of systemic immunosuppressants (aOR 3.76, 2.44-5.78). By contrast, pre-vaccination SARS-CoV-2 seropositivity (aOR 0.16, 0.04-0.70, for symptomatic seropositives vs seronegatives) and supplemental vitamin D intake (aOR 0.73, 0.53-0.99) were associated with reduced risk of post-vaccination seronegativity. 247/378 (65.3%) of participants who were seronegative after two doses of ChAdOx1 vs BNT162b2 provided a third sample at a median of 7.8 weeks (IQR 5.8-10.4) after

receiving a booster dose of BNT162b2 or mRNA-1273: eight (3.2%) of them remained seronegative after three vaccine doses, all of whom either had a primary immunodeficiency or were taking systemic immunosuppressant drugs.

**Interpretation:** We identify multiple determinants of antibody responses to two doses of ChAdOx1 or BNT162b2, many of which are potentially modifiable. Booster doses of BNT162b2 or mRNA-1273 were highly effective in achieving seroconversion in those who failed to mount antibody responses following two doses of ChAdOx1 or BNT162b2.

**Study registration:** <https://clinicaltrials.gov/ct2/show/NCT04330599>

**Funding:** Barts Charity, Fischer Family Trust, The Exilarch's Foundation, DSM Nutritional Products, Health Data Research UK

## **Research in context**

### **Evidence before this study**

We searched PubMed, medRxiv, and Google Scholar for papers published from January 1, 2020, to February 1, 2022, using the search terms (antibody OR humoral OR serologic\* OR immunogenic\*) AND (SARS-CoV-2 vaccine OR ChAdOx1 or BNT162b2 coronavirus), with no language restrictions. Population-based studies investigating multiple potential determinants of vaccine immunogenicity in people with known pre-vaccination SARS-CoV-2 serostatus are lacking.

### **Added value of this study**

This large population-based study, conducted in a population with known pre-vaccination SARS-CoV-2 serostatus, examines a comprehensive range of potential sociodemographic, behavioural, clinical, pharmacological and nutritional determinants of antibody responses to administration of two major SARS-CoV-2 vaccines (i.e., ChAdOx1 or BNT162b2), many of which have not previously been investigated. It is also the first population-based study to characterise antibody responses to booster doses of SARS-CoV-2 vaccines in adults who were seronegative after their primary course of vaccination.

### **Implications of all the available evidence**

Increased risk of seronegativity following two doses of SARS-CoV-2 vaccines was associated with administration of ChAdOx1 vs BNT162b2, shorter interval between first and second vaccine doses, poorer self-assessed general health, immunocompromise and SARS-CoV-2 seronegativity pre-vaccination. Regular intake of vitamin D supplements was associated with reduced risk of post-vaccination seronegativity. Randomised controlled trials are now needed to test for causality. Booster doses of BNT162b2 or mRNA-1273 were highly effective in achieving seroconversion in the majority of people who failed to mount antibody responses following a primary course of vaccination, the few exceptions being a subset of those with primary immunodeficiency or systemic immunosuppressant drugs.

## Introduction

Vaccination against SARS-CoV-2 represents a key tool for COVID-19 control. However, existing vaccines offer imperfect protection against disease, reflecting heterogeneity in immunogenicity.<sup>1,2</sup> Improved understanding of factors influencing immune responses to SARS-CoV-2 vaccines could lead to discovery of effect-modifiers that could be harnessed to augment vaccine immunogenicity, and identify groups of poor responders who might benefit from more intensive vaccine dosing regimens or implementation of other protective measures.<sup>3</sup>

Existing studies investigating determinants of vaccine immunogenicity have reported that lower antibody responses following SARS-CoV-2 vaccination associate with administration of viral vector vs messenger RNA (mRNA) vaccines, older age, poorer general health, immunosuppression and shorter inter-dose intervals.<sup>4-11</sup> Higher post-vaccination antibody titres are seen in those with evidence of SARS-CoV-2 infection before vaccination.<sup>9,12,13</sup> However, these studies are limited in several respects: many are conducted in specific populations such as health care workers<sup>5,9,12,13</sup> or in individuals with a particular demographic or clinical characteristic that may influence vaccine immunogenicity,<sup>6,10,11</sup> which may constrain generalisability of their results. Where population-based studies have been done,<sup>4,7,8</sup> these did not compare the effect of two doses of viral vector vs mRNA vaccines on host response; neither did they systematically ascertain participants' pre-vaccination SARS-CoV-2 serostatus, which is an important potential confounder of associations reported. Moreover, these studies did not investigate effects of modifiable factors that have been posited to influence responses to vaccination, such as time of day of inoculation,<sup>14</sup> nutrition,<sup>15</sup> sleep,<sup>16</sup> alcohol use,<sup>17</sup> tobacco smoking<sup>18</sup> and peri-vaccination use of anti-pyretic analgesics.<sup>19</sup> There is also a lack of population-based studies investigating responses to booster doses of SARS-CoV-2 vaccines in individuals who failed to mount an antibody response after their primary course of vaccination.

We sought to address these limitations by investigating a comprehensive range of potential sociodemographic, behavioural, clinical, pharmacological and nutritional determinants of antibody responses in a population-based cohort of UK adults (COVIDENCE UK)<sup>20</sup> following administration of two doses of either BNT162b2 (Pfizer-BioNTech) or ChAdOx1 nCoV-19 (Oxford-AstraZeneca; hereafter ChAdOx1) SARS-CoV-2 vaccines. Post-booster tests were offered to participants who were

seronegative after their primary course of vaccination. We utilised an assay with proven sensitivity for detection of combined IgG, IgA and IgM antibodies to the SARS-CoV-2 spike antigen<sup>21</sup> that has been validated as a correlate of protection against breakthrough COVID-19 in two populations.<sup>22,23</sup>

## Methods

### Study design and participants

COVIDENCE UK is a prospective, longitudinal, population-based observational study of COVID-19 in the UK population ([www.qmul.ac.uk/covidence](http://www.qmul.ac.uk/covidence)).<sup>20</sup> Inclusion criteria were age  $\geq 16$  years and UK residence at enrolment, with no exclusion criteria. Participants were invited *via* a national media campaign to complete an online baseline questionnaire to capture information on potential symptoms of COVID-19 experienced since February 1, 2020; results of any COVID-19 tests; and details of a wide range of potential risk factors for COVID-19 and determinants of vaccine response (Table S1, Supplementary Appendix). Online monthly follow-up questionnaires captured incident test-confirmed COVID-19 and vaccination details (Table S2, Supplementary Appendix), and a pre-vaccination serology study was conducted to evaluate risk factors for SARS-CoV-2 infection.<sup>24</sup> The study was launched on May 1, 2020, and closed to enrolment on October 6, 2021. Participants in the cohort were invited *via* email to participate in post-vaccination antibody studies and to give additional consent for these. The primary analysis presented here includes data from all participants for whom a serology result was available following administration of two doses of ChAdOx1 or BNT162b2; an additional antibody test following administration of a third booster dose of vaccine was offered to all participants who were seronegative after two vaccine doses, and a randomly selected subset of positive controls who were seropositive after two vaccine doses.

COVIDENCE UK was sponsored by Queen Mary University of London and approved by Leicester South Research Ethics Committee (ref 20/EM/0117). It is registered with ClinicalTrials.gov (NCT04330599).

## Procedures

Participants were sent kits containing instructions, lancets, and blood spot collection cards, to be posted back to the study team. Once returned, the samples were logged by the study team and sent in batches to the Clinical Immunology Service at the Institute of Immunology and Immunotherapy of the University of Birmingham (Birmingham, UK) for semi-quantitative determination of combined IgG, IgM and IgA anti-spike antibody titres using a commercially available ELISA that measures combined IgG, IgA, and IgM (IgGAM) responses to the SARS-CoV-2 trimeric spike glycoprotein (product code MK654; The Binding Site [TBS], Birmingham, UK). This assay has been CE-marked with 98.3% (95% Confidence Interval [CI] 96.4–99.4) specificity and 98.6% (92.6–100.0) sensitivity following reverse transcription polymerase chain reaction (RT-PCR)-confirmed mild-to-moderate COVID-19 that did not result in hospitalisation.<sup>25</sup> A cut-off ratio relative to the TBS cut-off calibrators was determined by plotting 624 pre-2019 negatives in a frequency histogram. A cut-off coefficient was then established for IgGAM (1.31), with ratio values classed as positive ( $\geq 1$ ) or negative ( $< 1$ ). Dried blood spot eluates were pre-diluted 1:40 with 0.05% PBS-Tween using a Dynex Revelation automated absorbance microplate reader (Dynex Technologies; Chantilly, VA, USA). Plates were developed after 10 min using 3,3',5,5'-tetramethylbenzidine core, and orthophosphoric acid used as a stop solution (both TBS). Optical densities at 450 nm were measured using the Dynex Revelation.

## Outcomes

Study outcomes were presence vs absence of antibodies against SARS-CoV-2 (analysed as a binary outcome) and antibody titres (continuous outcome restricted to the individuals who were seropositive after receiving two vaccine doses).

## Independent variables

Sixty-six putative determinants of post-vaccination serological responses were selected *a priori*, covering vaccination type and timing, sociodemographic, occupational, and lifestyle factors; longstanding medical conditions and prescribed medication use; Bacille Calmette Guérin (BCG) vaccine status, and diet and supplemental micronutrient intake (Tables S1-2, Supplementary Appendix). These factors, which were obtained from the baseline or monthly questionnaires, were included as independent variables in our models. To produce participant-level covariates for each class of medications investigated, questionnaire responses were mapped to drug classes listed in the British National Formulary (BNF) or the DrugBank



and Electronic Medicines Compendium databases if not explicitly listed in the BNF, as previously described.<sup>20</sup> Index of Multiple Deprivation (IMD) 2019 scores were assigned according to participants' postcodes, and categorised into quartiles.

## **Statistical analysis**

Full details of the sample size calculation and statistical analysis are provided in Supplementary Material. Briefly, logistic regression models were used to estimate adjusted ORs, 95% (CIs) and associated pairwise P-values for potential determinants of post-vaccination seronegativity in all participants. Linear regression models were used to estimate beta-coefficients, 95% CIs and associated pairwise P-values for potential determinants of log-transformed antibody titres in the subset of seropositive participants. For ease of interpretation, log-transformed estimates of antibody titres were exponentiated and a percentage increase or decrease was calculated for every one-unit increase in the potential determinant. We first estimated ORs and beta-coefficients in minimally adjusted models, and included factors independently associated with each outcome at the 10% significance level in fully adjusted models.

In a sensitivity analysis, we excluded participants from the analysis of antibody titres after two vaccine doses who reported a positive RT-PCR or lateral flow test for SARS-CoV-2 between the date of their second dose of vaccine and the date on which they provided their dried blood spot sample. We also stratified the analysis of antibody titres following two vaccine doses according to the type of vaccine received to explore whether determinants of antibody responses to two vaccine doses were consistent for ChAdOx1 vs BNT162b2. Given reports that peri-vaccination use of antipyretic analgesics may attenuate vaccine immunogenicity,<sup>26</sup> we also conducted an exploratory analysis to determine the influence of taking paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) to treat post-vaccination symptoms on post-vaccination antibody titres.

## **Role of the funding source**

The study funders had no role in the study design, data analysis, data interpretation, or writing of the report.

## Results

A total of 15,527 participants were invited to participate in the study of antibody responses following two vaccine doses, of whom 13,005 consented to take part. Serology results were available for 9,244 participants, of whom 9,101 received two doses of ChAdOx1 (n=5,770) or BNT162b2 (n=3,331) for their primary vaccination course and were included in this analysis (Figure S1, Supplementary Appendix). Their characteristics are presented in Table 1: median age was 64.2 years at enrolment (IQR 57.1, 69.9), 71.1% were female, and 96.5% were of White ethnic origin. Post-vaccination dried blood spot samples were provided from January 12 to September 18, 2021 by participants who received their first dose of vaccine from December 15, 2020 to July 10, 2021 and their second dose from January 5, 2021 to September 4, 2021. Median time from the date of participants' second vaccine dose to the date on which post-vaccination dried blood spot samples were provided was 8.6 weeks (IQR 6.4-10.7 weeks) and 374 of 9,101 participants (4.1%) were seronegative following two doses of vaccine. All of these participants, along with a randomly selected subset of 100 positive controls (who were seropositive after two doses of vaccine) were offered a third antibody test following administration of a single booster vaccine dose between September 23 to December 12, 2021. A total of 304 of these participants provided post-booster dried blood spot samples. Their characteristics are presented in Table S3: 261 received a BNT162b2 booster (221 after two doses of ChAdOx1 and 40 after two doses of BNT162b2) and 43 received a mRNA-1273 (Moderna) booster (all after two doses of ChAdOx1).

### ***Determinants of seronegativity following two vaccine doses***

Table 2 presents results of minimally adjusted and multivariable analyses to identify factors that were independently associated with the absence of detectable anti-spike IgG/A/M following two doses of ChAdOx1 or BNT162b2. After adjusting for age and sex, 32 independent variables associated with post-vaccination serostatus with  $P < 0.10$  and were fitted in a fully adjusted model. Ten factors in the fully adjusted model remained independently associated with post-vaccination serostatus ( $P < 0.05$ ). Eight of these were associated with higher risk of post-vaccination seronegativity: receiving ChAdOx1 vs BNT162b2 vaccine (aOR 7.03, 95% CI 4.39-11.24); shorter interval

between first and second vaccine doses (aOR 1.59, 1.18-2.13, for 6-10 weeks vs >10 weeks, and aOR 2.37, 1.06-5.26, for <6 weeks vs >10 weeks); older age (aOR per 10-year increase in age 1.68, 1.42-2.00), poorer self-assessed general health (aOR per level of declining health, 1.26, 1.09-1.45); immunodeficiency disorder (aOR 6.75, 2.63-17.35), and use of systemic immunosuppressants (aOR 3.76, 2.44-5.78), sodium-glucose co-transporter-2 inhibitors (aOR 3.75, 1.12-12.52) and anti-platelet agents (aOR 2.87, 1.08-7.64). Two factors were associated with lower risk of post-vaccination seronegativity: pre-vaccination seropositivity for SARS-CoV-2 (aOR 0.54, 0.32-0.90, for individuals who were seropositive without COVID-19 symptoms pre-vaccination vs those who were seronegative pre-vaccination, and aOR 0.16, 0.04-0.70, for individuals who were seropositive with COVID-19 symptoms pre-vaccination vs those who were seronegative pre-vaccination) and regular consumption of vitamin D supplements (aOR 0.68, 0.52-0.89). No associations were seen for other independent variables investigated, including time of day of inoculation, nutrition, sleep, alcohol use, tobacco smoking or socioeconomic deprivation.

### ***Determinants of post-vaccination antibody titres in subset of individuals who were seropositive following a primary course of SARS-CoV-2 vaccination***

To identify factors influencing the magnitude of antibody responses to COVID-19 vaccination, we investigated determinants of SARS-CoV-2 antibody titres in the subset of 8,727 participants who were seropositive following their second COVID-19 vaccine dose. Results of this analysis are presented in Table 3. A total of 22 factors associated with antibody titres after adjusting for age and sex with  $P < 0.10$  and were fitted in a fully adjusted model. Nine factors remained independently associated with antibody titres in the fully adjusted model with  $P < 0.05$ . Six of these independently associated with lower antibody titres: receipt of ChAdOx1 vs BNT162b2 vaccine (43.4% lower titres, 95% CI 41.8-44.9, Figure 1); longer duration between date of second vaccine dose and date of sampling (6.8% lower, 2.3-11.1, for 5-8 weeks vs 2-4 weeks; 12.1% lower, 7.5-16.4, for 9-16 weeks vs 2-4 weeks, and 11.1% lower, 4.2-17.4, for >16 weeks vs 2-4 weeks); shorter interval between first and second vaccine doses (11.1% lower, 4.2-17.4, for <6 weeks vs >10 weeks; 5.8% lower, 3.3-8.3, for 6-10 weeks vs >10 weeks); receiving the second vaccine dose during the first quarter (Q1) or the final

quarter (Q4) of the year (8.0% lower, 3.1-12.7, for Q1 vs Q2, and 47.7% lower, 11.4-69.1, for Q4 vs Q2); age  $\geq 80$  years (19.4% lower, 0.5-34.7 vs age  $< 30$  years), and presence of hypertension (4.0% lower, 1.0-6.9). Three factors independently associated with higher post-vaccination antibody titres: South Asian ethnicity (17.3% higher, 3.9-32.4, vs White ethnicity) or Mixed/Multiple/Other ethnicity (12.2% higher, 3.0-22.1, vs White ethnicity); higher body mass index (BMI; 2.9% higher, 0.2-5.7, for BMI 25-30 vs  $< 25$  kg/m<sup>2</sup>); and pre-vaccination seropositivity for SARS-CoV-2 (39.4% higher, 34.4-44.6, for individuals who were seropositive without COVID-19 symptoms pre-vaccination vs those who were seronegative pre-vaccination, and 117.9% higher, 105.6-130.9, for individuals who were seropositive with COVID-19 symptoms pre-vaccination vs those who were seronegative pre-vaccination). All the above determinants of post-vaccination antibody titres remained significant ( $P < 0.05$ ) when we performed a sensitivity analysis excluding 23 individuals who reported RT-PCR- or lateral flow test-confirmed SARS-CoV-2 infection after their second vaccine dose, but before their serology sampling date (data not shown).

### ***Stratification of antibody responses by vaccine type***

To explore whether determinants of antibody responses to vaccination were consistent for ChAdOx1 vs BNT162b2, we stratified the analysis of post-vaccination antibody titres according to type of vaccine received. Tables S4 and S5 (Supplementary Appendix) present the results of these analyses. Seven factors associated independently with post-vaccination antibody titres in ChAdOx1 recipients, but not in BNT162b2 recipients: lower titres in this group were associated with active cancer, consumption of selenium supplements and use of statins, Angiotensin Converting Enzyme (ACE) inhibitors and proton pump inhibitors (PPI), while South Asian and Mixed/Multiple/Other ethnic origin associated with higher titres. Conversely, three factors associated independently with lower post-vaccination antibody titres in BNT162b2 recipients, but not in ChAdOx1 recipients: older age, hypertension and use of systemic immunosuppressant medication. To test whether vaccine type modified the effects of these independent variables on post-vaccination antibody titres, we fitted all significant factors in our main multivariable model and included an interaction term for vaccine type. Three factors showed a small but statistically significant interaction:

hypertension ( $P_{\text{interaction}}=0.035$ ), regular consumption of selenium supplements ( $P_{\text{interaction}}=0.021$ ) and use of systemic immunosuppressant medication ( $P_{\text{interaction}}=0.046$ ; Figure S2, Supplementary Appendix).

### ***Influence of post-vaccination paracetamol / NSAIDs on antibody response to primary course of vaccination***

Results of an exploratory analysis to determine the influence of taking paracetamol or NSAIDs to treat post-vaccination symptoms are presented in Table S6. After fitting post-vaccination paracetamol/NSAID use into the main multivariable model we found a significant positive association between this factor and post-vaccination antibody titres. We then reasoned that this association could be confounded by an association between presence or severity of post-vaccination symptoms and higher post-vaccination antibody titres. After additionally correcting for report of post-vaccination symptoms (i.e., headache, fever, local soreness), the association between post-vaccination paracetamol/NSAID use and post-vaccination titres was rendered statistically non-significant.

### ***Antibody responses to booster doses in participants who were seronegative after two vaccine doses***

Anti-spike IgGAM titres for the subset of participants who provided dried blood spot samples following administration of a third vaccine dose are presented in Figure 2. Of 247 participants who had undetectable anti-spike IgGAM following two vaccine doses, all but eight (3.2%) had detectable antibodies following subsequent administration of a single booster dose. Details of the vaccine regimens, medical history and medication for the eight participants who remained seronegative following their booster dose are presented in Table S7, Supplementary Material: seven were taking immunosuppressant medication (five for autoimmune disease, two following solid organ transplant) and one had a primary antibody deficiency. Median post-booster antibody titres were higher among participants who were seropositive vs seronegative after two vaccine doses.

## Discussion

We present results of a large population-based study examining a comprehensive range of potential determinants of combined IgG, IgA and IgM responses to two very widely used SARS-CoV-2 vaccines. A major finding was that 5.8% of participants did not have detectable IgG/A/M anti-spike antibodies following two doses of ChAdOx1, as compared with 1.2% of those who had received two doses of BNT162b2 (aOR 7.03, 95% CI 4.39 to 11.24). Other risk factors for post-vaccination seronegativity included shorter inter-dose interval, older age, poorer general health, immunodeficiency disorder and use of systemic immunosuppressive medication. By contrast, pre-vaccination SARS-CoV-2 seropositivity and regular use of vitamin D supplements at the time of vaccination were associated with lower risk of post-vaccination seronegativity. Post-vaccination antibody titres were higher in participants of South Asian and mixed/other ethnic origin vs White participants, and in those who were overweight vs normal weight; these associations were independent of pre-vaccination SARS-CoV-2 serostatus. Post-vaccination use of paracetamol or NSAIDs was not associated with lower antibody responses to vaccination, after adjustment for post-vaccination symptoms, and determinants of post-vaccination anti-spike titres were not substantively different for participants who received two doses of ChAdOx1 vs BNT162b2. Single 'booster' doses of BNT162b2 or mRNA-1273 were highly effective in inducing seroconversion in the vast majority of adults who had undetectable anti-spike IgGAM antibodies after their first two doses of vaccine; those who failed to seroconvert after a booster dose were all taking immunosuppressant medication or had a primary immunodeficiency.

Our findings confirm previous reports of higher antibody responses to BNT162b2 vs ChAdOx1.<sup>4,13,27</sup> Pre-existing immunity to adenovirus vectors may be one of the factors underlying this difference,<sup>28</sup> and experiments to compare the prevalence of adenovirus neutralising antibody in pre-vaccination serum of participants who did vs did not develop anti-spike antibodies in response to ChAdOx1 are planned. Our finding that all participants who were seronegative after two doses of ChAdOx1 or BNT162b2 and who did not have an underlying immune defect seroconverted after receiving a single



booster dose of BNT162b2 or mRNA-1273 provides strong support for roll-out of third vaccine doses to achieve near-universal seroconversion in the general population.

Our results with respect to the adverse influence of older age, shorter inter-dose interval, poorer general health, immunodeficiency and immunosuppressants on post-vaccination antibody responses are also broadly consistent with those of others<sup>4-9</sup> – as is the finding that pre-vaccination SARS-CoV-2 infection associates with higher antibody titres after vaccination.<sup>9,12,13</sup> However, we also report a number of novel findings. The independent association between regular use of vitamin D supplements and reduced risk of post-vaccination seronegativity echoes results of a previous study where we showed that high-dose vitamin D replacement enhances antigen-specific cellular responses following vaccination against varicella zoster virus;<sup>29</sup> an intervention study nested within a randomised controlled trial of vitamin D supplementation for prevention of COVID-19 (ClinicalTrials.gov identifier NCT04579640) is currently ongoing to explore this finding further. Associations between increased risk of post-vaccination seronegativity and use of sodium-glucose co-transporter-2 (SGLT2) inhibitors or anti-platelet drugs have also not previously been reported to our knowledge. Both drug classes are recognised to have immunomodulatory actions,<sup>30,31</sup> but further studies are needed to determine whether the associations we report can be replicated in other cohorts.

We also found that White ethnicity and lower BMI both associated with lower post-vaccination antibody titres, independently of pre-vaccination SARS-CoV-2 serostatus. Ethnic variation in SARS-CoV-2 vaccine immunogenicity has not been widely studied to date: one study has reported lower antibody responses to vaccination in Jewish vs non-Jewish health care workers in Israel,<sup>9</sup> while a population-based UK study reported higher antibody titres in ‘non-Whites’ vs Whites. However, pre-vaccination serostatus was not available for all participants in these studies; this omission is potentially important, because unvaccinated people of South Asian ethnic origin were at higher risk of SARS-CoV-2 infection in the pre-vaccination era.<sup>20,24</sup> We demonstrate for the first time that higher anti-spike titres among vaccinated people of South Asian origin are not attributable to the higher rates of pre-vaccination SARS-CoV-2 infection that we have previously reported.<sup>20,24</sup> The reasons for this phenomenon require further investigation: ethnic variation in recognition of SARS-CoV-2 T cell epitopes is recognised,<sup>32</sup> and it may be that analogous variation in B cell epitopes underlies the

ethnic differences in antibody responses to vaccination seen here. By contrast with ethnicity, several studies have investigated the impact of BMI on post-vaccination antibody titres. Their results are inconsistent, with one reporting lower antibody responses in those with BMI >30 kg/m<sup>2</sup>,<sup>4</sup> another reporting higher responses in those with higher BMI<sup>33</sup> and two reporting no association.<sup>34,35</sup> Of note, studies investigating antibody responses to influenza vaccination report higher titres initially in obese participants, but a greater decline thereafter.<sup>36</sup> This finding highlights the importance of longer term follow-up to elucidate the influence of BMI on humoral responses to vaccination.

We also report some important null results. The lack of association between time of day of vaccination and degree of antibody response conflicts with findings of studies which variously report higher anti-spike responses in those vaccinated earlier<sup>37</sup> or later<sup>38</sup> in the day. We also show no association between pre- or post-vaccination use of paracetamol or NSAIDs and antibody responses, after adjustment for incidence of post-vaccination symptoms. This provides reassurance that use of these medications to manage reactive post-vaccination symptoms does not compromise SARS-CoV-2 vaccine immunogenicity. We also show no association between higher titres and socioeconomic deprivation, as reported by others;<sup>4,7</sup> this may reflect the fact that other studies did not adjust for pre-vaccination serostatus, which is more likely to be positive in socioeconomically deprived populations. There was no evidence of association for lifestyle factors hypothesised to influence vaccine responses including dietary factors, use of micronutrient supplements other than vitamin D, sleep, alcohol use and tobacco smoking.

Our study has several strengths. We utilised a CE-marked assay with high sensitivity and specificity that targets three different types of antibody,<sup>21</sup> and that we have validated as a correlate of protection against breakthrough disease.<sup>22,23</sup> Its large size affords power to detect determinants of having undetectable anti-spike antibodies after SARS-CoV-2 vaccination – a relatively rare, but potentially clinically important outcome. The population-based nature of this study, and the fact that we investigated effects of two major vaccines utilising differing technology (one live vector, one mRNA) enhances the generalisability of our findings. Very detailed characterisation of participants allowed us to investigate a wide range of potential determinants of vaccine



immunogenicity, and to adjust for multiple confounders, including pre-vaccination serostatus.

Our study also has some limitations. We did not study cellular responses to vaccination, and these may be discordant with humoral responses.<sup>10,27</sup> We also studied responses at an early time point only; a high early peak in antibody titres following vaccination is not necessarily an indicator of durable response.<sup>36</sup> As with any observational study, we cannot exclude the possibility that some of the associations we report might be explained by residual or unmeasured confounding. However, we have minimised the risk of this by adjusting for a comprehensive list of putative determinants of vaccine immunogenicity. COVIDENCE UK is also a self-selected cohort, and thus certain demographics—such as people <30 years old, people of lower socioeconomic status, and non-White ethnic groups—are under-represented. This may have limited our power to investigate antibody responses in some sub-groups, such as participants of Black ethnicity (who are at higher risk of SARS-CoV-2 infection<sup>39-41</sup> and adverse outcomes<sup>42</sup> than White people).

In conclusion, this large population-based study reports on the influence of a comprehensive range of potential sociodemographic, behavioural, clinical, pharmacological and nutritional determinants on antibody responses to two major SARS-CoV-2 vaccines. Importantly, we also show that booster doses of mRNA vaccines are highly effective in achieving seroconversion in healthy people who fail to mount antibody responses to SARS-CoV-2 trimeric spike glycoprotein after receiving two doses of ChAdOx1.

## **Contributors**

ARM wrote the study protocol, with input from DAJ, MT, and SOS. HH, MT, JS, GAD, RAL, CJG, FK, AS, and ARM contributed to questionnaire development and design. DAJ co-ordinated and managed the study, with input from ARM, NP, HH and SM. HH, JS, ARM, and SOS supported recruitment. SEF and AGR developed, validated, and performed laboratory assays. DAJ, MT, HH, MG, GV and FT contributed to data management. DAJ and ARM directly accessed and verified the data. Statistical analyses were done by DAJ, with input from ARM. DAJ and ARM wrote the first draft of the report. All authors revised it critically for important intellectual content, gave final

approval of the version to be published, and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work were appropriately investigated and resolved. DAJ, MT, HH, GV and FT had full access to all data in the study, and ARM had final responsibility for the decision to submit for publication.

### **Declaration of interests**

JS declares receipt of payments from Reach plc for news stories written about recruitment to, and findings of, the COVIDENCE UK study. AS is a member of the Scottish Government Chief Medical Officer's COVID-19 Advisory Group and its Standing Committee on Pandemics. He is also a member of the UK Government's NERVTAG's Risk Stratification Subgroup. ARM declares receipt of funding in the last 36 months to support vitamin D research from the following companies who manufacture or sell vitamin D supplements: Pharma Nord Ltd, DSM Nutritional Products Ltd, Thornton & Ross Ltd and Hyphens Pharma Ltd. ARM also declares support for attending meetings from the following companies who manufacture or sell vitamin D supplements: Pharma Nord Ltd and Abiogen Pharma Ltd. ARM also declares participation on the Data and Safety Monitoring Board for the Chair, DSMB, VITALITY trial (Vitamin D for Adolescents with HIV to reduce musculoskeletal morbidity and immunopathology). ARM also declares unpaid work as a Programme Committee member for the Vitamin D Workshop. ARM also declares receipt of vitamin D capsules for clinical trial use from Pharma Nord Ltd, Synergy Biologics Ltd and Cytoplan Ltd. All other authors declare no competing interests.

### **Data sharing**

De-identified participant data will be made available upon reasonable request to the corresponding author, subject to terms of Research Ethics Committee approval and Sponsor requirements.

### **Acknowledgments**

This study was supported by a grant from Barts Charity to ARM and CJG (MGU0466) and by donations to Queen Mary University of London from the Fischer Family Trust,

the Exilarch's Foundation and DSM Nutritional Products Ltd. DAJ is supported by a Barts Charity Lectureship (MGU0459). MT is supported by a grant from the Rosetrees Trust and The Bloom Foundation (M771). The work was carried out with the support of BREATHE - The Health Data Research Hub for Respiratory Health (MC\_PC\_19004) in partnership with SAIL Databank. BREATHE is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK. The views expressed are those of the authors and not necessarily those of the funders. We thank all participants of COVIDENCE UK, and the following organisations who supported study recruitment: Asthma UK, the British Heart Foundation, the British Lung Foundation, the British Obesity Society, Cancer Research UK, Diabetes UK, Future Publishing, Kidney Care UK, Kidney Wales, Mumsnet, the National Kidney Federation, the National Rheumatoid Arthritis Society, the North West London Health Research Register (DISCOVER), Primary Immunodeficiency UK, the Race Equality Foundation, SWM Health, the Terence Higgins Trust, and Vasculitis UK.

## References

1. Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. *N Engl J Med* 2021; **385**(16): 1474-84.
2. de la Monte SM, Long C, Szczepanski N, Griffin C, Fitzgerald A, Chapin K. Heterogeneous Longitudinal Antibody Responses to Covid-19 mRNA Vaccination. *Clin Pathol* 2021; **14**: 2632010X211049255.
3. Zimmermann P, Curtis N. Factors That Influence the Immune Response to Vaccination. *Clinical Microbiology Reviews* 2019; **32**(2).
4. Wei J, Stoesser N, Matthews PC, et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. *Nat Microbiol* 2021; **6**(9): 1140-9.
5. Payne RP, Longet S, Austin JA, et al. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. *Cell* 2021; **184**(23): 5699-714 e11.
6. Amirthalingam G, Bernal JL, Andrews NJ, et al. Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England. *Nature Communications* 2021; **12**(1): 7217.
7. Kertes J, Gez SB, Saciuk Y, et al. Effectiveness of mRNA BNT162b2 Vaccine 6 Months after Vaccination among Patients in Large Health Maintenance Organization, Israel. *Emerging Infectious Diseases* 2021; **28**(2).
8. Papadopoli R, De Sarro C, Palleria C, Gallelli L, Pileggi C, De Sarro G. Serological Response to SARS-CoV-2 Messenger RNA Vaccine: Real-World Evidence from Italian Adult Population. *Vaccines (Basel)* 2021; **9**(12).
9. Abu Jabal K, Ben-Amram H, Beiruti K, et al. Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021. *Euro Surveill* 2021; **26**(6).
10. Fernandez-Ruiz M, Almendro-Vazquez P, Carretero O, et al. Discordance Between SARS-CoV-2-specific Cell-mediated and Antibody Responses Elicited by mRNA-1273 Vaccine in Kidney and Liver Transplant Recipients. *Transplant Direct* 2021; **7**(12): e794.
11. Parry H, McIlroy G, Bruton R, et al. Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia. *Blood Cancer J* 2021; **11**(7): 136.
12. Manisty C, Otter AD, Treibel TA, et al. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. *Lancet* 2021; **397**(10279): 1057-8.
13. Eyre DW, Lumley SF, Wei J, et al. Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status. *Clin Microbiol Infect* 2021; **27**(10): 1516 e7- e14.
14. Long JE, Drayson MT, Taylor AE, Toellner KM, Lord JM, Phillips AC. Morning vaccination enhances antibody response over afternoon vaccination: A cluster-randomised trial. *Vaccine* 2016; **34**(24): 2679-85.
15. Rayman MP, Calder PC. Optimising COVID-19 vaccine efficacy by ensuring nutritional adequacy. *Br J Nutr* 2021; **126**(12): 1919-20.
16. Benedict C, Cedernaes J. Could a good night's sleep improve COVID-19 vaccine efficacy? *The Lancet Respiratory Medicine* 2021; **9**(5): 447-8.
17. Calina D, Hartung T, Mardare I, et al. COVID-19 pandemic and alcohol consumption: Impacts and interconnections. *Toxicol Rep* 2021; **8**: 529-35.
18. Ferrara P, Ponticelli D, Aguero F, et al. Does smoking have an impact on the immunological response to COVID-19 vaccines? Evidence from the VASCO study and need for further studies. *Public Health* 2022; **203**: 97-9.

19. Prymula R, Siegrist CA, Chlibek R, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. *Lancet* 2009; **374**(9698): 1339-50.
20. Holt H, Talaei M, Greenig M, et al. Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK). *Thorax* 2021.
21. Morley GL, Taylor S, Jossi S, et al. Sensitive Detection of SARS-CoV-2-Specific Antibodies in Dried Blood Spot Samples. *Emerging infectious diseases* 2020; **26**(12): 2970-3.
22. Shields AM, Faustini SE, Kristunas CA, et al. COVID-19: Seroprevalence and Vaccine Responses in UK Dental Care Professionals. *J Dent Res* 2021; **100**(11): 1220-7.
23. Vivaldi G, Jolliffe DA, Faustini SE, et al. Correlation between post-vaccination titres of IgG, IgA and IgM anti-Spike antibodies and protection against breakthrough SARS-CoV-2 infection: a population-based longitudinal study (COVIDENCE UK). *MedRxiv* 2022.
24. Talaei M, Faustini SE, Holt H, et al. Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK). *MedRxiv* 2022.
25. Cook AM, Faustini SE, Williams LJ, et al. Validation of a combined ELISA to detect IgG, IgA and IgM antibody responses to SARS-CoV-2 in mild or moderate non-hospitalised patients. *Journal of Immunological Methods* 2021; **494**: 113046.
26. Saleh E, Moody MA, Walter EB. Effect of antipyretic analgesics on immune responses to vaccination. *Hum Vaccin Immunother* 2016; **12**(9): 2391-402.
27. Parry H, Bruton R, Stephens C, et al. Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people. *Immun Ageing* 2021; **18**(1): 34.
28. Fausther-Bovendo H, Kobinger GP. Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important? *Hum Vaccin Immunother* 2014; **10**(10): 2875-84.
29. Chambers ES, Vukmanovic-Stejic M, Turner CT, et al. Vitamin D3 replacement enhances antigen-specific immunity in older adults. *Immunother Adv* 2020; (Itaa008).
30. Das L, Dutta P. SGLT2 inhibition and COVID-19: The road not taken. *Eur J Clin Invest* 2020; **50**(12): e13339.
31. Layne K, Di Giosia P, Ferro A, Passacquale G. Anti-platelet drugs attenuate the expansion of circulating CD14highCD16+ monocytes under pro-inflammatory conditions. *Cardiovasc Res* 2016; **111**(1): 26-33.
32. Bose T, Pant N, Pinna NK, Bhar S, Dutta A, Mande SS. Does immune recognition of SARS-CoV2 epitopes vary between different ethnic groups? *Virus Res* 2021; **305**: 198579.
33. Mishra SK, Pradhan SK, Pati S, Sahu S, Nanda RK. Waning of Anti-spike Antibodies in AZD1222 (ChAdOx1) Vaccinated Healthcare Providers: A Prospective Longitudinal Study. *Cureus* 2021; **13**(11): e19879.
34. Uysal EB, Gumus S, Bektore B, Bozkurt H, Gozalan A. Evaluation of antibody response after COVID-19 vaccination of healthcare workers. *J Med Virol* 2021.
35. Lee SW, Moon JY, Lee SK, et al. Anti-SARS-CoV-2 Spike Protein RBD Antibody Levels After Receiving a Second Dose of ChAdOx1 nCov-19 (AZD1222) Vaccine in Healthcare Workers: Lack of Association With Age, Sex, Obesity, and Adverse Reactions. *Front Immunol* 2021; **12**: 779212.
36. Sheridan PA, Paich HA, Handy J, et al. Obesity is associated with impaired immune response to influenza vaccination in humans. *Int J Obes (Lond)* 2012; **36**(8): 1072-7.
37. Zhang H, Liu Y, Liu D, et al. Time of day influences immune response to an inactivated vaccine against SARS-CoV-2. *Cell Res* 2021; **31**(11): 1215-7.
38. Wang W, Balfe P, Eyre DW, et al. Time of Day of Vaccination Affects SARS-CoV-2 Antibody Responses in an Observational Study of Health Care Workers. *J Biol Rhythms* 2021: 7487304211059315.
39. Ward H, Atchison C, Whitaker M, et al. SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic. *Nat Commun* 2021; **12**(1): 905.
40. Chadeau-Hyam M, Bodinier B, Elliott J, et al. Risk factors for positive and negative COVID-19 tests: a cautious and in-depth analysis of UK biobank data. *Int J Epidemiol* 2020; **49**(5): 1454-67.

41. Rozenfeld Y, Beam J, Maier H, et al. A model of disparities: risk factors associated with COVID-19 infection. *Int J Equity Health* 2020; **19**(1): 126-.
42. Mathur R, Rentsch CT, Morton CE, et al. Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform. *Lancet* 2021; **397**(10286): 1711-24.

**Table 1.** Participant characteristics, by vaccine type and overall (n=9,101)

Characteristic	ChAdOx1 (n=5,770)	BNT162b2 (n=3,331)	Overall (n=9,101)
Age	Median age, years (IQR)	63.5 (57.0 68.9)	64.2 (57.1 69.9)
	Age range, years	17.4 89.4	16.6 90.5
Sex, N (%)	Male	1671 (29.0)	956 (28.7)
	Female	4099 (71.0)	2375 (71.3)
Ethnicity, N (%) <sup>1</sup>	White	5565 (96.4)	3222 (96.7)
	South Asian	119 (2.1)	60 (1.8)
	Black/African/Caribbean/Black British	62 (1.1)	38 (1.1)
	Mixed/Multiple/Other	24 (0.4)	10 (0.3)
Nation of residence <sup>2</sup>	England	5177 (89.8)	2906 (87.3)
	Northern Ireland	39 (0.7)	78 (2.3)
	Scotland	358 (6.2)	199 (6.0)
	Wales	194 (3.4)	147 (4.4)
Body mass index, kg/m <sup>2</sup> , N (%) <sup>3</sup>	<25	2845 (49.3)	1596 (47.9)
	25-30	1881 (32.6)	1097 (32.9)
	>30	1034 (17.9)	636 (19.1)
Highest educational level attained, N (%) <sup>4</sup>	Primary/Secondary	636 (11)	401 (12)
	Higher/Further (A levels)	857 (14.9)	441 (13.2)
	College	2540 (44)	1500 (45)
	Post-graduate	1736 (30.1)	984 (29.5)
Quantiles of IMD rank, N (%) <sup>5</sup>	Q1 (most deprived)	1172 (20.3)	786 (23.6)
	Q2	1417 (24.6)	782 (23.5)
	Q3	1537 (26.6)	868 (26.1)
	Q4 (least deprived)	1639 (28.4)	893 (26.8)
Tobacco smoking, N (%)	Non-current/never smoker	5546 (96.1)	3194 (95.9)
	Current smoker	224 (3.9)	137 (4.1)
Alcohol consumption/week, units, N (%)	None	1505 (26.1)	896 (26.9)
	1-7	2018 (35)	1212 (36.4)
	8-14	1186 (20.6)	695 (20.9)
	15-21	593 (10.3)	310 (9.3)
	22-28	263 (4.6)	127 (3.8)
	>28	205 (3.6)	91 (2.7)
Self-assessed general health	Excellent	1183 (20.5)	654 (19.6)
	Very good	2336 (40.5)	1315 (39.5)
	Good	1441 (25.0)	925 (27.8)
	Fair	637 (11.0)	344 (10.3)
	Poor	173 (3.0)	93 (2.8)
Pre-vaccination anti-spike IgG/A/M serostatus	Negative	3789 (65.7)	1770 (53.1)
	Positive	696 (12.1)	325 (9.8)
	Unknown	1285 (22.3)	1236 (37.1)
Post-vaccination anti-spike IgG/A/M serostatus	Negative	334 (5.8)	40 (1.2)
	Positive	5436 (94.2)	3291 (98.8)
Median time from date of second vaccine dose to date of sampling, weeks (IQR)	7.6 (5.7-9.6)	10.1 (8.3-13.1)	8.6 (6.4-10.7)

Abbreviations: IQR, inter-quartile range; s.d., standard deviation; IMD, index of multiple deprivation; Ig, Immunoglobulin.

(1) Ethnicity not reported for n=1 who received BNT162b2 vaccine

(2) Nation of residence not reported for n=1 who received BNT162b2 vaccine and n=2 who received ChAdOx1 vaccine

(3) BMI not reported for n=10 who received BNT162b2 vaccine and n=2 who received ChAdOx1 vaccine

(4) Level of education not reported for n=5 who received BNT162b2 vaccine and n=1 who received ChAdOx1 vaccine

(5) IMD rank not reported for n=2 who received BNT162b2 vaccine and n=5 who received ChAdOx1 vaccine

**Table 2.** Determinants of post-vaccination seronegativity, all participants (n=9,101)

Predictor		N seronegative (%)	Minimally adjusted odds ratio (95% CI) <sup>1</sup>	Pairwise P value	Fully adjusted odds ratio (95% CI) <sup>2</sup>	Pairwise P value	P for trend
<b>Vaccine type and timing</b>							
<b>Vaccine type</b>	ChAdOx1	334/5770 (5.8)	5.49 (3.94, 7.66)	<0.001	7.03 (4.39, 11.24)	<0.001	-
	BNT162b2	40/3331 (1.2)	Referent				
<b>Time from date of second vaccine dose to date of sampling, weeks (IQR)</b>	<2	3/34 (8.8)	2.85 (0.80, 10.20)	0.11			
	2-4	19/593 (3.2)	Referent				
	5-8	127/3878 (3.3)	0.87 (0.53, 1.42)	0.57			
	9-16	213/4155 (5.1)	1.27 (0.78, 2.07)	0.33			
	>16	12/441 (2.7)	0.68 (0.33, 1.43)	0.31			
<b>Inter-dose interval, weeks</b>	<6	25/474 (5.3)	1.52 (0.99, 2.34)	0.054	2.37 (1.06, 5.26)	0.04	<0.001
	6-10	142/2959 (4.8)	1.47 (1.17, 1.83)	0.001	1.59 (1.18, 2.13)	0.002	
	>10	207/5668 (3.7)	Referent				
<b>Time of second vaccine dose</b>	Before 12 pm	148/3692 (4.0)	Referent				
	12 pm – 2 pm	74/1561 (4.7)	1.21 (0.91, 1.61)	0.19			
	2 pm – 5 pm	103/2573 (4.0)	1.01 (0.78, 1.31)	0.92			
	After 5 pm	30/941 (3.2)	0.84 (0.57, 1.26)	0.41			
<b>Quarter of second vaccine dose</b>	Q1	56/1318 (4.2)	1.02 (0.76, 1.37)	0.87	1.16 (0.65, 2.08)	0.62	-
	Q2	313/7755 (4.0)	Referent				
	Q3	2/13 (15.4)	4.10 (0.89, 18.77)	0.07	-		
	Q4	3/15 (20.0)	5.82 (1.60, 21.17)	0.007	-		
<b>Socio-demographic factors</b>							
<b>Age, years</b>	<30	3/83 (3.6)	Referent				<0.001
	30-39.99	6/192 (3.1)	0.87 (0.21, 3.57)	0.85	1.00 (0.09, 11.21)	0.99	
	40-49.99	11/595 (1.8)	0.51 (0.14, 1.85)	0.30	0.55 (0.06, 5.20)	0.60	
	50-59.99	62/2266 (2.7)	0.75 (0.23, 2.44)	0.63	0.88 (0.10, 7.50)	0.91	
	60-69.99	152/3706 (4.1)	1.11 (0.35, 3.55)	0.86	1.67 (0.20, 14.07)	0.64	
	70-79.99	131/2077 (6.3)	1.69 (0.52, 5.42)	0.38	3.03 (0.36, 25.85)	0.31	
	≥80	9/182 (4.9)	1.25 (0.33, 4.76)	0.74	3.57 (0.26, 49.42)	0.34	
<b>Sex</b>	Female	234/6474 (3.6)	Referent				
	Male	140/2627 (5.3)	1.33 (1.07, 1.66)	0.01	1.31 (0.97, 1.77)	0.07	-
<b>Ethnicity</b>	White	368/8787 (4.2)	Referent				
	Mixed/Multiple/Other	4/179 (2.2)	0.59 (0.22, 1.59)	0.30			
	South Asian	1/100 (1.0)	0.27 (0.04, 1.94)	0.19			
	Black/African/Caribbean/Black British	1/34 (2.9)	-				
<b>BMI, kg/m2</b>	<25	164/4441 (3.7)	Referent				0.71
	25-30	135/2978 (4.5)	1.20 (0.95, 1.52)	0.13	1.12 (0.83, 1.52)	0.47	
	>30	74/1670 (4.4)	1.30 (0.98, 1.72)	0.07	1.03 (0.69, 1.55)	0.88	
<b>Highest educational level attained</b>	Primary/Secondary	54/1036 (5.2)	1.12 (0.80, 1.57)	0.50			
	Higher/further (A levels)	56/1298 (4.3)	0.99 (0.72, 1.38)	0.97			
	College	150/4041 (3.7)	0.86 (0.67, 1.10)	0.23			



Predictor		N seronegative (%)	Minimally adjusted odds ratio (95% CI) <sup>1</sup>	Pairwise P value	Fully adjusted odds ratio (95% CI) <sup>2</sup>	Pairwise P value	P for trend
<b>Quantiles of IMD rank</b>	Post-graduate	114/2720 (4.2)	Referent				
	Q1 (most deprived)	85/1958 (4.3)	1.20 (0.89, 1.61)	0.24			
	Q2	94/2199 (4.3)	1.12 (0.84, 1.49)	0.45			
	Q3	96/2405 (4.0)	1.01 (0.76, 1.35)	0.92			
	Q4 (least deprived)	99/2532 (3.9)	Referent				
<b>Lifestyle factors</b>							
<b>Tobacco smoking</b>	No	363/8740 (4.2)	Referent				
	Yes	11/361 (3.0)	0.77 (0.42, 1.42)	0.40			
<b>Vaping</b>	No	364/8881 (4.1)	Referent				
	Yes	9/196 (4.6)	1.16 (0.59, 2.29)	0.67			
<b>Alcohol, units/week</b>	None	118/2401 (4.9)	Referent				0.81
	1-7	103/3230 (3.2)	0.63 (0.48, 0.82)	0.001	0.73 (0.51, 1.04)	0.08	
	8-14	84/1880 (4.5)	0.85 (0.64, 1.14)	0.29	1.16 (0.79, 1.69)	0.44	
	15-21	40/903 (4.4)	0.83 (0.57, 1.20)	0.31	1.04 (0.65, 1.68)	0.86	
	22-28	17/391 (4.3)	0.78 (0.46, 1.32)	0.35	1.20 (0.63, 2.28)	0.58	
	>28	12/296 (4.1)	0.71 (0.38, 1.30)	0.27	0.69 (0.29, 1.67)	0.41	
<b>Light exercise, hours/week</b>	0-4	140/2824 (5.0)	1.52 (1.18, 1.96)	0.001	1.16 (0.83, 1.64)	0.38	0.31
	5-9	120/2987 (4.0)	1.20 (0.93, 1.56)	0.17	1.10 (0.79, 1.52)	0.58	
	≥10	114/3268 (3.5)	Referent				
<b>Vigorous exercise, hours/week</b>	0	155/3458 (4.5)	1.19 (0.91, 1.56)	0.20			
	1-3	132/3387 (3.9)	1.04 (0.79, 1.37)	0.79			
	≥4	87/2230 (3.9)	Referent				
<b>Sleep, hours/night</b>	≤6	43/797 (5.4)	1.60 (1.12, 2.27)	0.009	1.51 (0.95, 2.38)	0.08	0.54
	7	93/2215 (4.2)	1.19 (0.91, 1.56)	0.21	1.09 (0.77, 1.55)	0.63	
	8	133/3750 (3.5)	Referent				
	≥9	105/2336 (4.5)	1.27 (0.98, 1.65)	0.07	1.22 (0.87, 1.70)	0.24	
<b>Self-assessed general health</b>	Excellent	52/1837 (2.8)	Referent				0.002
	Very good	136/3652 (3.7)	1.31 (0.95, 1.82)	0.10	1.58 (1.02, 2.43)	0.04	
	Good	100/2365 (4.2)	1.54 (1.09, 2.16)	0.01	1.93 (1.21, 3.08)	0.006	
	Fair	60/981 (6.1)	2.35 (1.60, 3.44)	<0.001	2.14 (1.23, 3.74)	0.007	
	Poor	26/266 (9.8)	3.85 (2.35, 6.28)	<0.001	3.33 (1.49, 7.46)	0.003	
<b>Anxiety or depression</b>	No	288/6910 (4.2)	Referent				
	Yes	86/2187 (3.9)	1.00 (0.78, 1.29)	0.98			
<b>Food choice</b>	None	362/8607 (4.2)	Referent				
	Vegetarian	9/380 (2.4)	0.59 (0.30, 1.15)	0.12			
	Vegan	3/114 (2.6)	0.63 (0.20, 2.01)	0.44			
<b>Medical conditions</b>							
<b>Heart disease <sup>3</sup></b>	No	351/8707 (4.0)	Referent				
	Yes	23/394 (5.8)	1.26 (0.81, 1.97)	0.30			
<b>Arterial disease <sup>4</sup></b>	No	340/8572 (4.0)	Referent				
	Yes	34/529 (6.4)	1.45 (1.00, 2.11)	0.05	0.49 (0.22, 1.08)	0.08	-
<b>Hypertension</b>	No	246/6902 (3.6)	Referent				
	Yes	128/2199 (5.8)	1.56 (1.25, 1.95)	<0.001	0.90 (0.58, 1.38)	0.63	-

Predictor		N seronegative (%)	Minimally adjusted odds ratio (95% CI) <sup>1</sup>	Pairwise P value	Fully adjusted odds ratio (95% CI) <sup>2</sup>	Pairwise P value	P for trend
<b>Immunodeficiency disorder <sup>5</sup></b>	No	364/9042 (4.0)	Referent				
	Yes	10/59 (16.9)	4.62 (2.32, 9.23)	<0.001	6.75 (2.63, 17.35)	<0.001	-
<b>Major neurological condition <sup>6</sup></b>	No	350/8833 (4.0)	Referent				
	Yes	24/268 (9.0)	2.23 (1.44, 3.44)	<0.001	1.79 (0.82, 3.94)	0.15	-
<b>Cancer</b>	Never	330/8128 (4.1)	Referent				
	Past (cured or in remission)	40/888 (4.5)	1.04 (0.74, 1.47)	0.80			
	Present (active)	4/85 (4.7)	1.00 (0.36, 2.77)	0.99			
<b>Asthma</b>	No	303/7652 (4.0)	Referent				
	Yes	71/1449 (4.9)	1.30 (1.00, 1.70)	0.05	1.01 (0.71, 1.45)	0.95	-
<b>COPD</b>	No	364/8905 (4.1)	Referent				
	Yes	10/196 (5.1)	1.19 (0.62, 2.27)	0.60			
<b>Diabetic status</b>	No diabetes	317/8334 (3.8)	Referent				0.06
	Pre-diabetes	16/296 (5.4)	1.38 (0.82, 2.31)	0.23	1.13 (0.57, 2.25)	0.72	
	Type 1 diabetes	4/69 (5.8)	1.59 (0.57, 4.41)	0.37	1.85 (0.51, 6.70)	0.35	
	Type 2 diabetes	34/385 (8.8)	2.26 (1.56, 3.28)	<0.001	1.73 (0.77, 3.87)	0.18	
<b>Atopy <sup>7</sup></b>	No	281/6794 (4.1)	Referent				
	Yes	93/2307 (4.0)	1.01 (0.80, 1.29)	0.92			
<b>Pre-vaccination SARS-COV-2 status</b>	Seronegative	226/5422 (4.2)	Referent				<0.001
	Seropositive, asymptomatic	18/722 (2.5)	0.58 (0.35, 0.94)	0.03	0.54 (0.32, 0.90)	0.02	
	Seropositive, symptomatic	2/264 (0.8)	0.20 (0.05, 0.81)	0.02	0.16 (0.04, 0.70)	0.01	
<b>Nutritional supplements</b>							
<b>Multivitamin</b>	No	299/7200 (4.2)	Referent				
	Yes	75/1901 (3.9)	0.98 (0.75, 1.26)	0.86			
<b>Vitamin A</b>	No	371/9053 (4.1)	Referent				
	Yes	3/48 (6.3)	1.56 (0.48, 5.04)	0.46			
<b>Vitamin C</b>	No	346/8192 (4.2)	Referent				
	Yes	28/909 (3.1)	0.73 (0.49, 1.08)	0.11			
<b>Vitamin D</b>	No	204/4455 (4.6)	Referent				
	Yes	170/4646 (3.7)	0.80 (0.65, 0.98)	0.03	0.68 (0.52, 0.89)	0.005	-
<b>Zinc</b>	No	357/8664 (4.1)	Referent				
	Yes	17/437 (3.9)	0.94 (0.57, 1.55)	0.82			
<b>Selenium</b>	No	372/9003 (4.1)	Referent				
	Yes	2/98 (2.0)	0.49 (0.12, 2.01)	0.32			
<b>Iron</b>	No	368/8816 (4.2)	Referent				
	Yes	6/285 (2.1)	0.53 (0.23, 1.19)	0.12			
<b>Probiotics</b>	No	359/8528 (4.2)	Referent				
	Yes	15/573 (2.6)	0.64 (0.38, 1.09)	0.10			
<b>Omega-3 fatty acids</b>	No	336/7975 (4.2)	Referent				
	Yes	38/1126 (3.4)	0.80 (0.57, 1.12)	0.19			
<b>Cod liver oil</b>	No	341/8279 (4.1)	Referent				

Predictor		N seronegative (%)	Minimally adjusted odds ratio (95% CI) <sup>1</sup>	Pairwise P value	Fully adjusted odds ratio (95% CI) <sup>2</sup>	Pairwise P value	P for trend
Garlic	Yes	33/822 (4.0)	0.93 (0.64, 1.34)	0.68			
	No	364/8907 (4.1)	Referent				
	Yes	10/194 (5.2)	1.20 (0.63, 2.30)	0.57			
<b>Medications</b>							
Beta-2 adrenergic agonists	No	334/8275 (4.0)	Referent				
	Yes	40/826 (4.8)	1.23 (0.87, 1.72)	0.24			
Beta blockers	No	334/8398 (4.0)	Referent				
	Yes	40/703 (5.7)	1.35 (0.96, 1.89)	0.09	1.04 (0.64, 1.69)	0.88	-
Statins	No	277/7337 (3.8)	Referent				
	Yes	97/1764 (5.5)	1.31 (1.02, 1.68)	0.03	0.90 (0.62, 1.31)	0.59	-
ACE inhibitors	No	320/8122 (3.9)	Referent				
	Yes	54/979 (5.5)	1.30 (0.96, 1.76)	0.09	1.16 (0.72, 1.87)	0.54	-
Proton pump inhibitors	No	287/7723 (3.7)	Referent				
	Yes	87/1378 (6.3)	1.69 (1.32, 2.16)	<0.001	0.90 (0.61, 1.32)	0.58	-
H2-receptor antagonists	No	373/9040 (4.1)	Referent				
	Yes	1/61 (1.6)	0.39 (0.05, 2.80)	0.35			
Inhaled corticosteroids	No	349/8505 (4.1)	Referent				
	Yes	25/596 (4.2)	1.01 (0.66, 1.53)	0.98			
Bronchodilators	No	333/8240 (4.0)	Referent				
	Yes	41/861 (4.8)	1.20 (0.85, 1.67)	0.30			
Systemic Immunosuppressants	No	327/8630 (3.8)	Referent				
	Yes	47/471 (10.0)	2.86 (2.08, 3.95)	<0.001	3.76 (2.44, 5.78)	<0.001	-
Angiotensin receptor blockers	No	331/8493 (3.9)	Referent				
	Yes	43/608 (7.1)	1.75 (1.25, 2.43)	<0.001	0.91 (0.53, 1.59)	0.75	-
SSRI antidepressants	No	350/8533 (4.1)	Referent				
	Yes	24/568 (4.2)	1.11 (0.73, 1.70)	0.62			
Non-SSRIs antidepressants	No	352/8726 (4.0)	Referent				
	Yes	22/375 (5.9)	1.57 (1.01, 2.46)	0.05	0.72 (0.35, 1.49)	0.38	-
Calcium channel blockers	No	314/8100 (3.9)	Referent				
	Yes	60/1001 (6.0)	1.45 (1.09, 1.94)	0.01	1.00 (0.64, 1.56)	0.99	-
Thiazide diuretics	No	359/8765 (4.1)	Referent				
	Yes	15/336 (4.5)	1.04 (0.61, 1.76)	0.89			
Vitamin K antagonists	No	370/9027 (4.1)	Referent				
	Yes	4/74 (5.4)	1.17 (0.42, 3.23)	0.76			
SGLT-2 inhibitors	No	369/9054 (4.1)	Referent				
	Yes	5/47 (10.6)	2.56 (1.01, 6.54)	0.05	3.75 (1.12, 12.52)	0.03	-
Anticholinergics	No	354/8656 (4.1)	Referent				
	Yes	20/445 (4.5)	1.08 (0.67, 1.72)	0.76			
Metformin	No	353/8827 (4.0)	Referent				
	Yes	21/274 (7.7)	1.83 (1.16, 2.90)	0.01	0.55 (0.2, 1.49)	0.24	-
Bisphosphonates	No	362/8912 (4.1)	Referent				
	Yes	12/189 (6.3)	1.72 (0.94, 3.12)	0.08	0.80 (0.33, 1.98)	0.63	-

Predictor		N seronegative (%)	Minimally adjusted odds ratio (95% CI) <sup>1</sup>	Pairwise P value	Fully adjusted odds ratio (95% CI) <sup>2</sup>	Pairwise P value	P for trend
<b>Anti-platelet drugs</b>	No	328/8453 (3.9)	Referent				
	Yes	46/648 (7.1)	1.67 (1.21, 2.32)	0.002	2.87 (1.08, 7.64)	0.03	-
<b>Sex hormone therapy</b>	No	347/8376 (4.1)	Referent				
	Yes	27/725 (3.7)	1.04 (0.69, 1.56)	0.87			
<b>Aspirin <sup>8</sup></b>	No	341/8593 (4.0)	Referent				
	Yes	33/508 (6.5)	1.47 (1.01, 2.14)	0.04	0.37 (0.14, 1.01)	0.05	-
<b>Paracetamol <sup>8</sup></b>	No	345/8677 (4.0)	Referent				
	Yes	29/424 (6.8)	1.77 (1.19, 2.62)	0.005	0.87 (0.48, 1.56)	0.63	-
<b>BCG vaccinated</b>	No	44/1075 (4.1)	Referent				
	Yes	280/7166 (3.9)	0.99 (0.71, 1.37)	0.13			

Abbreviations: CI, confidence interval; BMI, body mass index; IMD, index of multiple deprivation; COPD, chronic obstructive pulmonary disease; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; COVID-19, coronavirus disease 2019; ACE, angiotensin-converting enzyme; H2, histamine 2; SSRI, selective serotonin reuptake inhibitor; BCG, Bacille Calmette-Guérin ; SGLT2, sodium-glucose cotransporter-2

(1) Adjusted for age and sex only

(2) Adjusted for age, sex, vaccine type, inter-dose interval, quarter of second vaccination, BMI, alcohol intake, light exercise, sleep, self-assessed general health, arterial disease, hypertension, immunodeficiency disorder, major neurological condition, asthma, diabetic status, pre-vaccination SARS-CoV-2 status and pre-vaccination use of vitamin D supplements, beta blockers, statins, ACE inhibitors, proton pump inhibitors, systemic immunosuppressants, angiotensin receptor blockers, non-SSRI antidepressants, calcium channel blockers, SGLT2 inhibitors, metformin, bisphosphonates, anti-platelet drugs use, aspirin and paracetamol.

(3) Heart disease defined as coronary artery disease or heart failure

(4) Arterial disease defined as ischaemic heart disease, peripheral vascular disease or cerebrovascular disease

(5) Immunodeficiency defined as HIV, primary immune deficiency or other immunodeficiency

(6) Major neurological conditions defined as stroke, transient ischaemic attack, dementia, Parkinson's disease, multiple sclerosis or motor neurone disease

(7) Atopy defined as atopic eczema/dermatitis and/or hay fever/allergic rhinitis

(8) Chronic use prior to vaccination (i.e. distinct from acute post-vaccination use for treatment of reactogenic symptoms)

**Table 3.** Determinants of post-vaccination antibody titres, subset of seropositive participants (n=8,727)

Predictor	N	Median IgGAM ratio (IQR)	Minimally adjusted % difference (95% CI) <sup>1</sup>	P value	Fully adjusted % difference (95% CI) <sup>2</sup>	Pairwise P value	P for trend
<b>Vaccine type and timing</b>							
<b>Vaccine type</b>	ChAdOx1	5436 (62.3)	2.39 (1.76, 3.30)	-39.35 (-40.65, -38.02)	<0.001	-43.36 (-44.87, -41.82)	<0.001
	BNT162b2	3291 (37.7)	3.96 (3.15, 4.86)	Referent			-
<b>Time from second vaccine dose to sampling, weeks</b>	<2	31 (0.4)	2.96 (2.23, 13.62)	36.68 (11.82, 67.05)	0.002	0.5 (-19.23, 25.05)	0.96
	2-4	574 (6.6)	2.86 (2.06, 4.05)	Referent			<0.001
	5-8	3751 (43.0)	2.81 (1.95, 3.99)	-0.59 (-5.37, 4.43)	0.81	-6.83 (-11.12, -2.33)	0.003
	9-16	3942 (45.2)	3.13 (2.10, 4.24)	7.54 (2.33, 13.01)	0.004	-12.08 (-16.43, -7.51)	<0.001
	>16	429 (4.9)	2.93 (2.03, 4.43)	7.14 (-0.08, 14.89)	0.05	-5.9 (-14.61, 3.69)	0.219
<b>Inter-dose interval, weeks</b>	<6	449 (5.1)	2.91 (1.94, 4.12)	-1.23 (-6.38, 4.21)	0.65	-11.06 (-17.42, -4.22)	0.002
	6-10	2817 (32.3)	2.89 (2.00, 4.01)	-5.12 (-7.51, -2.66)	<0.001	-5.82 (-8.29, -3.27)	<0.001
	>10	5461 (62.6)	2.99 (2.06, 4.21)	Referent			
<b>Time of second vaccine dose</b>	Before 12 pm	3544/8412 (42.1)	2.92 (2.02, 4.10)	Referent			0.96+
	12 pm – 2 pm	1487/8412 (17.7)	2.91 (2.00, 4.07)	-1.12 (-4.39, 2.26)	0.51	-2.41 (-5.58, 0.88)	0.15
	2 pm – 5 pm	2470/8412 (29.4)	3.03 (2.06, 4.21)	2.88 (-0.01, 5.86)	0.05	1.2 (-1.6, 4.07)	0.41
	After 5 pm	911/8412 (10.8)	2.98 (2.07, 4.07)	0.54 (-3.45, 4.70)	0.79	-2.69 (-6.54, 1.31)	0.18
<b>Quarter of second vaccine dose</b>	Q1	1262 (14.5)	3.44 (2.42, 4.43)	15.46 (11.70, 19.34)	<0.001	-8.01 (-12.69, -3.22)	0.001
	Q2	7442 (85.3)	2.88 (1.99, 4.09)	Referent			0.004+
	Q3	11 (0.1)	3.17 (1.36, 4.47)	-3.37 (-30.38, 34.12)	0.84	31.63 (-22.10, 122.40)	0.30
	Q4	12 (0.1)	1.93 (1.28, 3.24)	-24.08 (-44.54, 3.92)	0.09	-47.69 (-69.11, -11.39)	0.02
<b>Socio-demographic factors</b>							
<b>Age, years</b>	<30	80/8727 (0.9)	3.79 (2.48, 4.85)	Referent			<0.001
	30-39.99	186/8727 (2.1)	3.43 (2.34, 4.55)	-12.71 (-24.56, 1.00)	0.07	-5.81 (-20.36, 11.39)	0.48
	40-49.99	584/8727 (6.7)	3.13 (2.16, 4.31)	-16.59 (-26.77, -5.01)	0.006	-4.04 (-17.55, 11.67)	0.59
	50-59.99	2204/8727 (25.3)	3.10 (2.14, 4.30)	-16.58 (-26.32, -5.55)	0.004	0.8 (-12.95, 16.73)	0.92
	60-69.99	3554/8727 (40.7)	2.85 (1.98, 4.05)	-22.79 (-31.75, -12.65)	<0.001	-5.32 (-18.21, 9.61)	0.47
	70-79.99	1946/8727 (22.3)	2.92 (1.96, 4.03)	-23.08 (-32.09, -12.87)	<0.001	-10.51 (-22.79, 3.71)	0.14
	≥80	173/8727 (2.0)	2.80 (1.84, 3.78)	-24.71 (-35.06, -12.72)	<0.001	-19.37 (-34.65, -0.5)	0.05
<b>Sex</b>	Female	6240/8727 (71.5)	3.01 (2.07, 4.19)	Referent			
	Male	2487/8727 (28.5)	2.87 (1.95, 4.04)	-3.17 (-5.68, -0.58)	0.02	-2.27 (-4.88, 0.41)	0.10
<b>Ethnicity</b>	White	8419/8726 (96.5)	2.94 (2.02, 4.11)	Referent			<0.001+
	Mixed/Multiple/Other	175/8726 (2.0)	3.35 (2.24, 4.73)	12.78 (3.75, 22.59)	0.005	12.16 (3.01, 22.12)	0.008
	South Asian	99/8726 (1.1)	3.46 (2.58, 4.64)	16.26 (4.10, 29.85)	0.008	17.29 (3.87, 32.44)	0.01
	Black/African/Caribbean/Black British	33/8726 (0.4)	3.54 (2.39, 5.46)	26.76 (4.79, 53.33)	0.015	8.65 (-10.34, 31.66)	0.40
<b>BMI, kg/m2</b>	<25	4277/8716 (49.1)	2.90 (2.03, 4.03)	Referent			0.038

Predictor	N	Median IgGAM ratio (IQR)	Minimally adjusted % difference (95% CI) <sup>1</sup>	P value	Fully adjusted % difference (95% CI) <sup>2</sup>	Pairwise P value	P for trend	
<b>Highest educational level attained</b>	25-30	2843/8716 (32.6)	2.96 (2.04, 4.15)	3.62 (0.91, 6.40)	0.009	2.92 (0.17, 5.74)	0.04	0.37
	>30	1596/8716 (18.3)	3.17 (2.02, 4.36)	4.87 (1.56, 8.29)	0.004	2.58 (-0.92, 6.2)	0.15	
	Primary/Secondary	983/8721 (11.3)	3.02 (1.93, 4.29)	1.05 (1.01, 1.10)	0.018	1.83 (-2.31, 6.15)	0.39	
	Higher/further (A levels)	1242/8721 (14.2)	2.98 (2.07, 4.14)	1.03 (1.00, 1.07)	0.07	1.53 (-2.24, 5.45)	0.43	
<b>Quantiles of IMD rank</b>	College	3890/8721 (44.6)	2.99 (2.07, 4.11)	1.04 (1.01, 1.07)	0.009	3.33 (0.51, 6.22)	0.02	
	Post-graduate	2606/8721 (29.9)	2.89 (1.98, 4.10)	Referent				
	Q1 (most deprived)	1872/8720 (21.5)	3.06 (2.12, 4.24)	2.28 (-1.10, 5.79)	0.19			
	Q2	2106/8720 (24.2)	2.97 (1.98, 4.19)	0.53 (-2.68, 3.85)	0.75			
	Q3	2309/8720 (26.5)	2.90 (2.04, 4.01)	-1.34 (-4.42, 1.84)	0.41			
<b>Lifestyle factors</b>								
	<b>Tobacco smoking</b>							
	No	8377/8727 (96.0)	2.95 (2.03, 4.13)	Referent				
	Yes	350/8727 (4.0)	3.20 (2.24, 4.20)	1.22 (-4.65, 7.46)	0.69			
<b>Vaping</b>	No	8517/8704 (97.9)	2.95 (2.03, 4.13)	Referent				
	Yes	187/8704 (2.1)	3.37 (2.18, 4.37)	5.47 (-2.73, 14.37)	0.20			
<b>Alcohol, units/week</b>	None	2283/8727 (26.2)	2.97 (2.05, 4.20)	Referent			0.71	
	1-7	3127/8727 (35.8)	3.03 (2.06, 4.14)	-0.68 (-3.63, 2.35)	0.66	1.32 (-1.73, 4.48)	0.40	
	8-14	1796/8727 (20.6)	2.94 (2.02, 4.16)	-1.87 (-5.21, 1.58)	0.28	0.65 (-2.85, 4.27)	0.72	
	15-21	863/8727 (9.9)	2.91 (1.98, 4.01)	-3.31 (-7.46, 1.03)	0.13	-0.08 (-4.37, 4.4)	0.97	
	22-28	374/8727 (4.3)	2.65 (1.91, 3.94)	-6.32 (-11.90, -0.39)	0.04	-4.55 (-10.15, 1.41)	0.13	
	>28	284/8727 (3.3)	2.84 (2.03, 4.18)	-3.06 (-9.56, 3.90)	0.38	0.01 (-6.68, 7.19)	1.00	
<b>Light exercise, hours/week</b>	0-4	2684/8705 (30.8)	3.07 (2.10, 4.26)	5.22 (2.21, 8.31)	0.001	0.21 (-2.82, 3.33)	0.90	0.92
	5-9	2867/8705 (32.9)	2.95 (2.02, 4.13)	1.29 (-1.54, 4.20)	0.38	-1.03 (-3.81, 1.84)	0.48	
	≥10	3154/8705 (36.2)	2.88 (1.99, 4.06)	Referent				
<b>Vigorous exercise, hours/week</b>	0	3303/8701 (38.0)	3.02 (2.05, 4.21)	4.97 (1.82, 8.21)	0.002	1.53 (-1.67, 4.84)	0.35	0.45
	1-3	3255/8701 (37.4)	2.98 (2.05, 4.12)	3.09 (-0.01, 6.28)	0.05	0.55 (-2.46, 3.66)	0.72	
	≥4	2143/8701 (24.6)	2.86 (1.99, 4.06)	Referent				
<b>Sleep, hours/night</b>	≤6	754/8724 (8.6)	3.07 (2.13, 4.29)	7.14 (2.55, 11.94)	0.002	3.44 (-1.12, 8.21)	0.14	0.94
	7	2122/8724 (24.3)	3.00 (2.04, 4.19)	3.05 (0.02, 6.18)	0.05	1.43 (-1.56, 4.5)	0.35	
	8	3617/8724 (41.5)	2.92 (2.00, 4.08)	Referent				
	≥9	2231/8724 (25.6)	2.96 (2.05, 4.13)	2.06 (-0.90, 5.10)	0.18	2.19 (-0.76, 5.24)	0.15	
<b>Self-assessed general health</b>	Excellent	1785/8727 (20.5)	2.92 (2.05, 4.07)	Referent			0.27	
	Very good	3516/8727 (40.3)	2.92 (2.01, 4.09)	-0.20 (-3.32, 3.02)	0.90	-2.01 (-5.06, 1.14)	0.21	
	Good	2265/8727 (26.0)	3.03 (2.06, 4.23)	4.73 (1.17, 8.42)	0.009	-0.41 (-3.94, 3.25)	0.82	
	Fair	921/8727 (10.6)	3.07 (2.02, 4.15)	2.38 (-2.07, 7.03)	0.30	-1.69 (-6.23, 3.08)	0.48	
	Poor	240/8727 (2.8)	2.95 (2.04, 4.39)	5.60 (-2.04, 13.84)	0.16	-7.1 (-14.38, 0.79)	0.08	
<b>Anxiety or depression</b>	No	6622/8723 (75.9)	2.95 (2.03, 4.13)	Referent				
	Yes	2101/8723 (24.1)	2.99 (2.03, 4.17)	0.68 (-2.06, 3.50)	0.63			
<b>Food choice</b>	None	8245/8727 (94.5)	2.96 (2.03, 4.13)	Referent				

Predictor		N	Median IgGAM ratio (IQR)	Minimally adjusted % difference (95% CI) <sup>1</sup>	P value	Fully adjusted % difference (95% CI) <sup>2</sup>	Pairwise P value	P for trend
	Vegetarian	371/8727 (4.3)	2.92 (2.04, 4.13)	-2.98 (-8.46, 2.83)	0.31			
	Vegan	111/8727 (1.3)	2.61 (2.00, 4.33)	-2.04 (-11.76, 8.74)	0.70			
<b>Medical conditions</b>								
<b>Heart disease</b> <sup>3</sup>	No	8356/8727 (95.7)	2.97 (2.03, 4.13)	Referent				
	Yes	371/8727 (4.3)	2.76 (1.93, 4.17)	1.33 (-4.46, 7.48)	0.66			
<b>Arterial disease</b> <sup>4</sup>	No	8232/8727 (94.3)	2.96 (2.04, 4.13)	Referent				
	Yes	495/8727 (5.7)	2.96 (1.94, 4.14)	2.02 (-3.09, 7.40)	0.45			
<b>Hypertension</b>	No	6656/8727 (76.3)	2.98 (2.06, 4.16)	Referent				
	Yes	2071/8727 (23.7)	2.89 (1.92, 4.08)	-2.62 (-5.32, 0.14)	0.06	-3.96 (-6.85, -0.98)	0.01	-
<b>Immunodeficiency disorder</b> <sup>5</sup>	No	8678/8727 (99.4)	2.96 (2.03, 4.13)	Referent				
	Yes	49/8727 (0.6)	2.85 (1.98, 3.96)	-0.17 (-14.65, 16.77)	0.98			
<b>Major neurological condition</b> <sup>6</sup>	No	8483/8727 (97.2)	2.96 (2.04, 4.13)	Referent				
	Yes	244/8727 (2.8)	2.90 (1.84, 4.10)	-0.74 (-7.55, 6.57)	0.84			
<b>Cancer</b>	Never	7798/8727 (89.4)	2.95 (2.04, 4.13)	Referent				
	Past (cured or in remission)	848/8727 (9.7)	2.99 (2.00, 4.15)	1.24 (-2.72, 5.35)	0.55			
	Present (active)	81/8727 (0.9)	2.93 (1.89, 3.82)	-5.33 (-16.23, 7.00)	0.38			
<b>Asthma</b>	No	7349/8727 (84.2)	2.97 (2.03, 4.14)	Referent				
	Yes	1378/8727 (15.8)	2.91 (2.06, 4.10)	-0.74 (-3.88, 2.51)	0.65			
<b>COPD</b>	No	8541/8727 (97.9)	2.96 (2.03, 4.13)	Referent				
	Yes	186/8727 (2.1)	3.06 (1.98, 4.12)	2.97 (-5.06, 11.67)	0.48			
<b>Diabetic status</b>	No diabetes	8017/8713 (92.0)	2.97 (2.04, 4.14)	Referent				
	Pre-diabetes	280/8713 (3.2)	2.68 (1.87, 3.93)	-4.13 (-10.31, 2.46)	0.21			
	Type 1 diabetes	65/8713 (0.7)	3.13 (1.95, 4.10)	-1.81 (-14.31, 12.52)	0.79			
	Type 2 diabetes	351/8713 (4.0)	2.95 (1.88, 4.30)	0.77 (-5.09, 6.98)	0.80			
<b>Atopy</b> <sup>7</sup>	No	6513/8727 (74.6)	2.95 (2.02, 4.14)	Referent				
	Yes	2214/8727 (25.4)	2.97 (2.05, 4.11)	-0.14 (-2.80, 2.59)	0.92			
<b>Pre-vaccination SARS-COV-2 status</b>	Seronegative	5196/6162 (84.3)	2.74 (1.92, 3.80)	Referent				
	Seropositive, asymptomatic	704/6162 (11.4)	3.62 (2.40, 5.01)	37.37 (31.83, 43.13)	<0.001	39.41 (34.37, 44.64)	<0.001	<0.001
	Seropositive, symptomatic	262/6162 (4.3)	5.50 (4.17, 12.62)	126.30 (112.07, 141.5)	<0.001	117.88 (105.55, 130.94)	<0.001	
<b>Nutritional supplements</b>								
<b>Multivitamin</b>	No	6901/8727 (79.1)	2.97 (2.03, 4.13)	Referent				
	Yes	1826/8727 (20.9)	2.91 (2.05, 4.17)	-0.64 (-3.46, 2.26)	0.66			
<b>Vitamin A</b>	No	8682/8727 (99.5)	2.96 (2.03, 4.13)	Referent				
	Yes	45/8727 (0.5)	2.90 (1.94, 3.93)	-4.11 (-18.56, 12.91)	0.61			
<b>Vitamin C</b>	No	7846/8727 (89.9)	2.95 (2.02, 4.11)	Referent				

Predictor		N	Median IgGAM ratio (IQR)	Minimally adjusted % difference (95% CI) <sup>1</sup>	P value	Fully adjusted % difference (95% CI) <sup>2</sup>	Pairwise P value	P for trend
<b>Vitamin D</b>	Yes	881/8727 (10.1)	3.13 (2.10, 4.26)	4.07 (0.10, 8.19)	0.04	1.32 (-2.59, 5.39)	0.52	-
	No	4251/8727 (48.7)	2.98 (2.05, 4.12)	Referent				
<b>Zinc</b>	Yes	4476/8727 (51.3)	2.94 (2.02, 4.15)	-0.87 (-3.16, 1.49)	0.47			
	No	8307/8727 (95.2)	2.96 (2.03, 4.13)	Referent				
<b>Selenium</b>	Yes	420/8727 (4.8)	2.91 (2.07, 4.18)	1.48 (-3.92, 7.18)	0.60			
	No	8631/8727 (98.9)	2.96 (2.03, 4.13)	Referent				
<b>Iron</b>	Yes	96/8727 (1.1)	2.57 (1.85, 4.06)	-6.21 (-16.16, 4.92)	0.26			
	No	8448/8727 (96.8)	2.96 (2.04, 4.13)	Referent				
<b>Probiotics</b>	Yes	279/8727 (3.2)	2.80 (1.88, 4.10)	-3.18 (-9.42, 3.49)	0.34			
	No	8169/8727 (93.6)	2.97 (2.03, 4.13)	Referent				
<b>Omega-3 fatty acids</b>	Yes	558/8727 (6.4)	2.87 (2.08, 4.27)	0.52 (-4.18, 5.45)	0.83			
	No	7639/8727 (87.5)	2.95 (2.02, 4.13)	Referent				
<b>Cod liver oil</b>	Yes	1088/8727 (12.5)	3.01 (2.12, 4.21)	3.08 (-0.51, 6.80)	0.09	2.4 (-1.2, 6.13)	0.19	-
	No	7938/8727 (91.0)	2.96 (2.04, 4.13)	Referent				
<b>Garlic</b>	Yes	789/8727 (9.0)	2.97 (2.00, 4.12)	1.15 (-2.90, 5.38)	0.58			
	No	8543/8727 (97.9)	2.95 (2.03, 4.13)	Referent				
<b>Medications</b>	Yes	184/8727 (2.1)	3.06 (2.26, 4.42)	6.51 (-1.83, 15.55)	0.13			
	No	8543/8727 (97.9)	2.95 (2.03, 4.13)	Referent				
<b>Beta-2 adrenergic agonists</b>	Yes	7941/8727 (91.0)	2.96 (2.03, 4.13)	Referent	0.69			
	No	786/8727 (9.0)	2.94 (2.05, 4.13)	0.83 (-3.21, 5.04)				
<b>Beta blockers</b>	Yes	8064/8727 (92.4)	2.97 (2.04, 4.13)	Referent	0.60			
	No	663/8727 (7.6)	2.87 (1.94, 4.11)	-1.17 (-5.47, 3.32)				
<b>Statins</b>	Yes	7060/8727 (80.9)	2.98 (2.06, 4.17)	Referent	0.11			
	No	1667/8727 (19.1)	2.86 (1.91, 4.01)	-2.52 (-5.51, 0.57)				
<b>ACE inhibitors</b>	Yes	7802/8727 (89.4)	2.97 (2.05, 4.14)	Referent	0.34			
	No	925/8727 (10.6)	2.89 (1.85, 4.09)	-1.85 (-5.55, 2.00)				
<b>Proton pump inhibitors</b>	Yes	7436/8727 (85.2)	2.97 (2.05, 4.13)	Referent	0.88			
	No	1291/8727 (14.8)	2.91 (1.92, 4.16)	0.26 (-3.00, 3.63)				
<b>H2-receptor antagonists</b>	Yes	8667/8727 (99.3)	2.96 (2.03, 4.13)	Referent	0.83			
	No	60/8727 (0.7)	3.02 (2.09, 4.20)	1.57 (-11.84, 17.01)				
<b>Inhaled corticosteroids</b>	Yes	8156/8727 (93.5)	2.96 (2.03, 4.13)	Referent	0.86			
	No	571/8727 (6.5)	2.88 (2.03, 4.11)	-0.44 (-5.04, 4.39)				
<b>Bronchodilators</b>	Yes	7907/8727 (90.6)	2.96 (2.03, 4.13)	Referent	0.32			
	No	820/8727 (9.4)	2.97 (2.08, 4.18)	2.06 (-1.95, 6.24)				
<b>Systemic immunosuppressants</b>	Yes	8303/8727 (95.1)	2.97 (2.04, 4.14)	Referent	0.11			
	No	424/8727 (4.9)	2.80 (1.99, 3.91)	-4.33 (-9.40, 1.02)				
<b>Angiotensin receptor blockers</b>	Yes	8162/8727 (93.5)	2.96 (2.04, 4.14)	Referent	0.33			
	No	565/8727 (6.5)	2.94 (1.93, 4.03)	-2.33 (-6.89, 2.45)				
<b>SSRI antidepressants</b>	Yes	8183/8727 (93.8)	2.95 (2.03, 4.11)	Referent	0.04	-0.42 (-5.33, 4.75)	0.87	-
	No	544/8727 (6.2)	3.17 (2.08, 4.33)	5.15 (0.17, 10.39)				



Predictor		N	Median IgGAM ratio (IQR)	Minimally adjusted % difference (95% CI) <sup>1</sup>	P value	Fully adjusted % difference (95% CI) <sup>2</sup>	Pairwise P value	P for trend
<b>Non-SSRIs antidepressants</b>	No	8374/8727 (96.0)	2.95 (2.03, 4.13)	Referent				
	Yes	353/8727 (4.0)	2.98 (2.01, 4.18)	2.24 (-3.66, 8.51)	0.46			
<b>Calcium channel blockers</b>	No	7786/8727 (89.2)	2.96 (2.05, 4.14)	Referent				
	Yes	941/8727 (10.8)	2.94 (1.92, 4.11)	-1.54 (-5.23, 2.29)	0.43			
<b>Thiazide diuretics</b>	No	8406/8727 (96.3)	2.97 (2.04, 4.14)	Referent				
	Yes	321/8727 (3.7)	2.75 (1.84, 3.95)	-5.56 (-11.27, 0.52)	0.07	-2.54 (-8.74, 4.08)	0.44	-
<b>Vitamin K antagonists</b>	No	8657/8727 (99.2)	2.96 (2.03, 4.14)	Referent				
	Yes	70/8727 (0.8)	2.94 (1.89, 3.81)	-5.97 (-17.55, 7.23)	0.36			
<b>SGLT2 inhibitors</b>	No	8685/8727 (99.5)	2.95 (2.03, 4.13)	Referent				
	Yes	42/8727 (0.5)	3.93 (2.44, 4.86)	10.26 (-6.90, 30.57)	0.26			
<b>Anticholinergics</b>	No	8302/8727 (95.1)	2.96 (2.03, 4.13)	Referent				
	Yes	425/8727 (4.9)	3.04 (2.11, 4.18)	3.08 (-2.38, 8.84)	0.27			
<b>Metformin</b>	No	8474/8727 (97.1)	2.95 (2.03, 4.12)	Referent				
	Yes	253/8727 (2.9)	3.20 (2.02, 4.46)	6.77 (-0.44, 14.50)	0.07	1.3 (-5.66, 8.76)	0.72	-
<b>Bisphosphonates</b>	No	8550/8727 (98.0)	2.96 (2.03, 4.13)	Referent				
	Yes	177/8727 (2.0)	2.73 (1.99, 4.16)	-1.09 (-8.99, 7.50)	0.80			
<b>Anti-platelet drugs</b>	No	8125/8727 (93.1)	2.97 (2.04, 4.14)	Referent				
	Yes	602/8727 (6.9)	2.87 (1.88, 4.05)	0.49 (-4.12, 5.32)	0.84			
<b>Sex hormone therapy</b>	No	8029/8727 (92.0)	2.95 (2.03, 4.13)	Referent				
	Yes	698/8727 (8.0)	3.06 (2.08, 4.18)	0.53 (-3.77, 5.03)	0.81			
<b>Aspirin <sup>8</sup></b>	No	8252/8727 (94.6)	2.97 (2.04, 4.13)	Referent				
	Yes	475/8727 (5.4)	2.84 (1.89, 4.11)	0.01 (-5.09, 5.39)	1.00			
<b>Paracetamol <sup>8</sup></b>	No	8332/8727 (95.5)	2.95 (2.03, 4.13)	Referent				
	Yes	395/8727 (4.5)	3.03 (1.99, 4.23)	2.81 (-2.82, 8.76)	0.34			
<b>BCG vaccinated</b>	No	1031/8710 (11.8)	2.86 (2.05, 4.07)	Referent				
	Yes	6886/8710 (79.1)	3.00 (2.05, 4.17)	2.77 (-0.92, 6.59)	0.65			

Abbreviations: IQR, inter-quartile range; CI, confidence interval; BMI, body mass index; Ig, immunoglobulin ; IMD, index of multiple deprivation; COPD, chronic obstructive pulmonary disease; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; COVID-19, coronavirus disease 2019; ACE, angiotensin-converting enzyme; H2, histamine 2; SSRI, selective serotonin reuptake inhibitor; BCG, Bacille Calmette-Guérin ; SGLT2, sodium-glucose cotransporter-2.

(1) Adjusted for age and sex only

(2) Adjusted for age, sex, vaccine type, time from second dose to sampling, inter-dose interval, time of second vaccination, quarter of second vaccination, ethnicity, BMI, educational level, alcohol intake, light exercise, vigorous exercise, sleep, self-assessed general health, hypertension, pre-vaccination SARS-CoV-2 status and pre-vaccination use of vitamin C supplements, omega-3 fatty acid supplements, SSRI antidepressants, thiazide diuretics and metformin(3) Heart disease defined as coronary artery disease or heart failure

(4) Arterial disease defined as ischaemic heart disease, peripheral vascular disease or cerebrovascular disease

(5) Immunodeficiency defined as HIV, primary immune deficiency or other immunodeficiency


(6) Major neurological conditions defined as stroke, transient ischaemic attack, dementia, Parkinson's disease, multiple sclerosis or motor neurone disease

(7) Atopy defined as atopic eczema/dermatitis and/or hay fever/allergic rhinitis

(8) Chronic use prior to vaccination (i.e. distinct from acute post-vaccination use for treatment of reactogenic symptoms)

† Global P value presented for this non-scalar categorical variable

**Figure 1.** Antibody titres following two doses of vaccine by type of vaccine (A), age (B), ethnicity (C) and pre-vaccination SARS-CoV-2 status (D). For C, South Asian indicates people who self-identified their ethnic origin as Indian, Pakistani, or Bangladeshi, and Black indicates people who self-identified their ethnic origin as Black, African, Caribbean or Black British. P values from Mann Whitney test (A) and Kruskal Wallis tests (B-D). Anti-S, anti-spike; IgGAM, immunoglobulin G, A or M. Dotted line = limit of detection.



**Figure 2. Anti-spike IgG/A/M titres before and after booster doses in participants who were seronegative vs seropositive after their primary course of SARS-CoV-2 vaccination.** (A), participants receiving ChAdOx1 primary course with BNT162b2 booster. (B), participants receiving ChAdOx1 primary course with mRNA-1273 booster. (C), participants receiving BNT162b2 primary course with BNT162b2 booster. P values for paired / unpaired comparisons from Wilcoxon matched pairs signed rank tests and Mann Whitney tests, respectively. Anti-S, anti-spike; IgGAM, immunoglobulin G, A or M. Dotted line = limit of detection.

